Kayzoni (Crizotinib) 250mg Capsules | TLPH Laos Generic Xalkori for ALK+ NSCLC | GLT

REQUEST A QUOTE

For individuals and institutions — pricing, availability, and product documents (COA) provided within 24 hours.
Direct line: [email protected] · +86 15234153837

مشاركة
Product description

Generic Information: Kayzoni (Crizotinib) 250 mg — TLPH Laos

Kayzoni is the crizotinib 250 mg capsule of TLPH — Tongmeng (Lao) Pharmaceutical and Food Co., Ltd — packed 60 capsules per carton with a tamper-evident pharmacy seal. Founded as the first GMP-certified medicine manufacturer in Laos, TLPH has grown its approved portfolio past fifty products spanning oncology, chronic disease and rare-disease therapies, and its anti-counterfeit verification system lets any patient check a pack's legitimacy before swallowing a single capsule.

What Is Kayzoni Indicated For?

Kayzoni carries crizotinib for molecularly selected lung cancer: ALK-positive or ROS1-positive advanced non-small cell lung cancer confirmed by validated testing. The molecule's wider reference roles — ALK-positive systemic ALCL in patients one year and older plus young adults, and unresectable/recurrent ALK-positive inflammatory myofibroblastic tumor — are recognized internationally, and GLT routinely helps families assemble the paperwork these rarer diagnoses require.

How Does Kayzoni Work?

The capsule inhibits ALK, ROS1, c-Met and RON receptor tyrosine kinases. ALK and ROS1 rearrangements weld together hybrid genes whose protein products drive growth signals without pause; crizotinib blocks those proteins' ATP-binding sites, dampening the signaling cascades below and pushing fusion-dependent tumor cells into a death program. Benefit is confined to patients whose tumors carry the target — molecular testing decides everything.

Indications List

  • ALK-positive locally advanced or metastatic NSCLC
  • ROS1-positive advanced NSCLC
  • Reference practice: ALK-positive ALCL (age ≥1 year, young adults) and ALK-positive IMT

Dosage and Administration

The standard adult pattern is 250 mg by mouth twice daily, close to every twelve hours, independent of meals but away from grapefruit. Capsules stay whole — no crushing. For toxicity management, physicians reduce stepwise; pronounced renal impairment converts the schedule to once daily. Continue until disease progression or until side effects outweigh benefit, always under oncology supervision.

Side Effects of Kayzoni

Day-to-day effects run toward transient visual glows, nausea, loose bowel movements, constipation, peripheral swelling and fatigue, plus elevated liver enzymes on scheduled blood draws. The critical safety flags are hepatotoxicity, ILD/pneumonitis, QT-interval prolongation, slow heart rate and severe visual loss. Regular liver testing, ECGs and electrolyte review form the monitoring backbone; early dose holds and reductions manage most events without ending therapy.

Storage

Keep below 30°C in a dry place inside the original carton. Ambient-temperature shipping is appropriate; refrigeration is unnecessary for this capsule.

Why Choose the GLT?

TLPH has become one of the most recognizable Lao manufacturers regionally — the company even participates in cross-border pharmaceutical procurement initiatives with Chinese provincial platforms — and Kayzoni is its answer for ALK/ROS1 therapy. GLT makes that supply reachable worldwide: licensed in Hong Kong, we verify every batch, photograph actual stock before dispatch, declare contents honestly for customs, and track each parcel door to door. Patients, caregivers and clinics all get one dedicated coordinator on WhatsApp from first question to last refill.

How to Order Kayzoni from GLT

Send your prescription and ALK/ROS1 report to WhatsApp +86 15234153837 or [email protected]. GLT confirms the 60-capsule Kayzoni pack price, verifies the anti-counterfeit code for you, and arranges insured international delivery with complete documentation.

FAQ

Q1: Who makes Kayzoni crizotinib?
TLPH — Tongmeng (Lao) Pharmaceutical and Food Co., Ltd — Laos' first GMP-certified drug manufacturer.

Q2: Is Kayzoni a real alternative to Xalkori?
Yes — same crizotinib molecule at 250 mg, produced under GMP, at a fraction of originator pricing.

Q3: How can I verify my Kayzoni pack is genuine?
TLPH packs carry a security code; GLT verifies it for you before dispatch and shares the check result in writing.

Q4: Where can I buy Kayzoni 250mg?
From GLT: WhatsApp +86 15234153837 or [email protected] — documents in, tracked parcel out.

Q5: What storage does Kayzoni need?
Below 30°C, dry, original carton — ordinary room conditions during shipping and at home are fine.

Related Oncology Products

بالوتيني (باريسيتينيب) 4ملغ | مثبط JAK1/JAK2 جنيس | ترانس كونتيننتال لايف ساينس آند فارماسيوتيكالز (TLPH) | GLT

باريسيتينيب جنيس (مثبط JAK1/JAK2) من ترانس كونتيننتال لايف ساينس آند فارماسيوتيكالز (TLPH) (لاوس) — بديل...

إلترومبوباغ (Promacta) أقراص 25/50 ملغ | ناهض TPO-R أصلي أمريكي | GLT

Promacta الأصلي من Novartis (إلترومبوباغ) 25 ملغ و50 ملغ، 30 قرصًا

مونجارو كويك بن (تيرزيباتيد) 10–60ملغ/2.4مل قلم متعدد الجرعات | إيلي ليلي (الولايات المتحدة) | GLT

مونجارو كويك بن — قلم إيلي ليلي متعدد الجرعات لمريض واحد، بست جرعات أمريكية (10–60ملغ/2.4مل،...

بارينات (باريسيتينيب) 4ملغ | مثبط JAK1/JAK2 جنيس | ناتكو فارما المحدودة | GLT

باريسيتينيب جنيس (مثبط JAK1/JAK2) من ناتكو فارما المحدودة (الهند) — بديل ميسور التكلفة عن أولوميانت...

أورفورغليبرون (OriYo) أقراص 0.8–17.2 ملغ | دواء جينيريك بنغلاديشي فموي GLP-1 | GLT

جينيريك أورفورغليبرون من National Drug Co. (بنغلاديش)، نظام معايرة من 6 جرعات لإدارة الوزن

SPINRAZA (نوسينرسن) 12 ملغ/5 مل | الشراء من الصين | علاج الضمور العضلي الشوكي | GLT

أول أوليغونوكليوتيد مضاد للمعنى من فئته من Biogen لعلاج الضمور العضلي الشوكي، معتمد من NMPA...

لوسيافات (أفاترومبوباغ) 20ملغ*28 قرصاً | لوسيوس للأدوية (لاوس) | GLT

لوسيافات — أقراص أفاترومبوباغ 20ملغ (ماليات 23.6ملغ) مطلية بغشاء من لوسيوس للأدوية (لاوس) المحدودة، فيينتيان.

KangQuXin 康曲欣 (أفاترومبوباغ) 20 ملغ × 10 أقراص | Beijing Continent (Gyre) | GLT

KangQuXin — أفاترومبوباغ من Beijing Continent Pharmaceutical (Gyre Therapeutics، ناسداك: GYRE)، الصين